Clinical Trials Logo

Solid Tumors, Adult clinical trials

View clinical trials related to Solid Tumors, Adult.

Filter by:

NCT ID: NCT05018273 Active, not recruiting - Solid Tumors, Adult Clinical Trials

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Start date: December 21, 2021
Phase: Phase 1
Study type: Interventional

A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination with atezolizumab, and to identify a RP2D for VB10.NEO in combination with atezolizumab, in patients with locally advanced and metastatic tumors that have progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care (SOC).

NCT ID: NCT04739293 Recruiting - Solid Tumors, Adult Clinical Trials

Study of ON 123300 in Patients With Advanced Cancer

Start date: May 13, 2021
Phase: Phase 1
Study type: Interventional

This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.

NCT ID: NCT04621435 Recruiting - Metastatic Cancer Clinical Trials

Imaging of Solid Tumors Using FAP-2286

Start date: December 14, 2020
Phase: Phase 1
Study type: Interventional

This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.

NCT ID: NCT04587479 Recruiting - Solid Tumors, Adult Clinical Trials

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

Start date: November 23, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.

NCT ID: NCT04467853 Terminated - Solid Tumors, Adult Clinical Trials

A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors

Start date: September 21, 2020
Phase: Phase 1
Study type: Interventional

This is a prospective, single-arm, open-label Phase 1 dose-finding and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the cell-based LCAR-C18S (hereinafter "LCAR-C18S") in subjects with Claudin18.2-positive advanced solid Tumors.